CA3216137A1 - Pharmaceutical composition for use in treating cerebral infarction - Google Patents

Pharmaceutical composition for use in treating cerebral infarction Download PDF

Info

Publication number
CA3216137A1
CA3216137A1 CA3216137A CA3216137A CA3216137A1 CA 3216137 A1 CA3216137 A1 CA 3216137A1 CA 3216137 A CA3216137 A CA 3216137A CA 3216137 A CA3216137 A CA 3216137A CA 3216137 A1 CA3216137 A1 CA 3216137A1
Authority
CA
Canada
Prior art keywords
pharmaceutical composition
composition according
cerebral infarction
administered
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3216137A
Other languages
English (en)
French (fr)
Inventor
Naoko Nishimura
Keiji Hasumi
Kazuo Honda
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Corxel Pharmaceuticals Hong Kong Ltd
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA3216137A1 publication Critical patent/CA3216137A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
CA3216137A 2021-05-10 2022-05-10 Pharmaceutical composition for use in treating cerebral infarction Pending CA3216137A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2021079820 2021-05-10
JP2021-079820 2021-05-10
PCT/US2022/028488 WO2022240810A1 (en) 2021-05-10 2022-05-10 Pharmaceutical composition for use in treating cerebral infarction

Publications (1)

Publication Number Publication Date
CA3216137A1 true CA3216137A1 (en) 2022-11-17

Family

ID=82214306

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3216137A Pending CA3216137A1 (en) 2021-05-10 2022-05-10 Pharmaceutical composition for use in treating cerebral infarction

Country Status (9)

Country Link
US (1) US20240238248A1 (enExample)
EP (1) EP4337193A1 (enExample)
JP (1) JP2024525998A (enExample)
KR (1) KR20240005749A (enExample)
CN (1) CN117295497A (enExample)
AU (1) AU2022275263A1 (enExample)
BR (1) BR112023023534A2 (enExample)
CA (1) CA3216137A1 (enExample)
WO (1) WO2022240810A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022226013A1 (en) * 2021-04-20 2022-10-27 Biogen Ma Inc. Pharmaceutical composition comprising the compound smtp-7
WO2026092761A1 (zh) * 2024-11-04 2026-05-07 江苏恒瑞医药股份有限公司 包含smtp衍生物的药物组合物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004224737A (ja) * 2003-01-23 2004-08-12 Ttc:Kk 新規トリプレニルフェノール化合物
JP4313049B2 (ja) 2003-01-23 2009-08-12 株式会社ティーティーシー 血管新生関連疾患の予防又は治療用医薬組成物
KR20080112184A (ko) 2006-03-27 2008-12-24 노우코우다이 티엘오 가부시키가이샤 트리프레닐페놀화합물과 트리프레닐페놀화합물의 제조방법,및 혈전용해촉진제
JP5605659B2 (ja) * 2009-07-06 2014-10-15 国立大学法人東京農工大学 細胞保護剤
JP7381035B2 (ja) * 2018-11-02 2023-11-15 学校法人昭和大学 Ｓｍｔｐ一群又はｓｍｔｐ－７の製造中間体及びその化学的製造方法
CN121064221A (zh) * 2021-02-10 2025-12-05 福建盛迪医药有限公司 一种smtp-7衍生物及其用途
WO2022226013A1 (en) * 2021-04-20 2022-10-27 Biogen Ma Inc. Pharmaceutical composition comprising the compound smtp-7

Also Published As

Publication number Publication date
AU2022275263A1 (en) 2023-11-09
EP4337193A1 (en) 2024-03-20
BR112023023534A2 (pt) 2024-01-30
JP2024525998A (ja) 2024-07-16
US20240238248A1 (en) 2024-07-18
KR20240005749A (ko) 2024-01-12
CN117295497A (zh) 2023-12-26
WO2022240810A1 (en) 2022-11-17

Similar Documents

Publication Publication Date Title
US20220152053A1 (en) Methods and compositions for treating various disorders
JP7042531B2 (ja) デオキシコール酸を含む医薬組成物
BR112021007725A2 (pt) métodos e composições para tratamento de presbiopia, midríase e outros distúrbios oculares
US20240238248A1 (en) Pharmaceutical composition for use in treating cerebral infarction
US20090076105A1 (en) Preventive or therapeutic agent for cerebral ischemic injury or cerebral ischemia reperfusion in stroke
AU2019354784B2 (en) Biphenyl sulfonamide compounds for the treatment of type IV collagen diseases
HEATH et al. Use of Phenylephrine Hydrochloride (Neo-Synephrine Hydrochloride®) in Ophthalmology
US20240238252A1 (en) Pharmaceutical composition comprising the compound smtp-7
US20050255096A1 (en) Combination treatment for acute myocardial infarction
HK40105798A (en) Pharmaceutical composition for use in treating cerebral infarction
US12171766B2 (en) Methods of treating patients suffering from brain injury and methods of increasing the value of the extended Glasgow Outcome Scale of patients suffering from brain injury
KR20120038982A (ko) 노령 및 신장 손상 ｓｔ 비상승 심근 경색 환자의 치료를 위한 오타믹사반
KR101805939B1 (ko) 치환된 감마 락탐을 함유하는 안과 제제 및 이의 사용 방법
Seestedt Jr et al. Intracerebral hemorrhage
JP4966019B2 (ja) 慢性移植片対宿主症におけるドライアイの予防および治療剤
IWAOKA et al. High Plasma Renin Activities in Primary Aldosteronism with Malignant Hypertension A Case Report
HK40105250A (en) Pharmaceutical composition comprising the compound smtp-7
US20130253027A1 (en) Dosages of arylsulfonamide derivatives
US7252835B2 (en) Agent for preventing and/or treating sinusitis
WO2025191274A1 (en) Treatment of stroke
WO2025018279A1 (ja) ヒト移植片対宿主病の治療薬およびその組合せ物
WO2021136549A1 (zh) 马来酸桂哌齐特用于制备防治脑卒中的药物中的应用
Aronson Domenic A. Sica
WO2007013842A1 (en) Use of 4-((tert-butylimino)methyl) benzene-1,3-disulfonate n-oxide against maemorrhagic changes in the brain
Watson Principles of General Management and Treatment

Legal Events

Date Code Title Description
R11 Change to the name of applicant or owner or transfer of ownership requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-R10-R11-R103 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CHANGE OF NAME REQUEST RECEIVED

Effective date: 20250313

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250313

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250428

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250428

R13 Change to the name of applicant or owner recorded

Free format text: ST27 STATUS EVENT CODE: A-1-1-R10-R13-R104 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CHANGE OF NAME REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250619

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD

Year of fee payment: 4

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260428

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260428

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED

Effective date: 20260501

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT

Effective date: 20260501

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260501

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20260506

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT

Effective date: 20260506

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20260506

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20260506

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260506

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260506

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260513